The German pharmaceutical company Merck KGaA is negotiating the acquisition of the American manufacturer of drugs for the treatment of cancer and rare diseases SpringWorks Therapeutics Inc. This is reported by foreign media.
The market capitalization of SpringWorks is $3.4 billion.
A Merck representative announced that various options for the deal are being considered, which is expected to be concluded within a few weeks.
Merck KGaA is a German pharmaceutical, chemical and biological company. The company produces biomedical products, biopharmaceutical and high-tech materials. The headquarters is located in Darmstadt (Germany) with offices in the USA and China.
SpringWorks Therapeutics, Inc. is an American biopharmaceutical company developing and selling drugs for the treatment of rare diseases and cancer. One of Ogsiveo's drugs is approved in the United States for the treatment of adults with connective tissue tumors. The headquarters is located in Stamford, Connecticut.
Read also in our Telegram channel "Mergers and acquisitions. AK&M».
